wasmhi2003_15.xml Guide to the Immunex Corporation Records 1983-2002 Immunex Corporation Records Finding aid prepared by Julie Kerssen Funding for encoding this finding aid was provided through a grant awarded by the National Endowment for the Humanities. Museum of History & Industry © 2006
5933 6th Avenue South Seattle, WA 98108 Phone: 206-324-1126 URL: http://www.mohai.org
Finding aid encoded by ArchProteus2006 Finding aid is in English Finding aid based on DACS ( Describing Archives: A Content Standard) Museum of History & Industry, Sophie Frye Bass Library
5933 6th Avenue South Seattle, WA 98108 Phone: 206-324-1126 URL: http://www.mohai.org
2003.15 Immunex (Firm) Immunex Corporation Records 1983-2002 4 boxes 2.5 linear feet Annual reports, news clippings, and other materials documenting biotechnology company Immunex from its founding in 1981 to its 2001 acquisition by Amgen. 15a.1.9 Collection materials are in English. Historical Note:

Scientists Steven Gillis and Christopher Henney, along with businessman Stephen Duzan, founded Immunex in July 1981. They envisioned the company's mission as developing, producing, and licensing diagnostic and therapeutic immunological products. Its successful drugs included LEUKINE (sargramostin) for patients undergoing bone marrow transplants, NOVANTRONE for multiple sclerosis, and ENBREL (etanercept), an anti-inflammatory used to treat arthritis. By 2001 Immunex was the largest biotechnology company in Washington State. At the end of that year, Amgen acquired the company for $16 billion.

See the "What's Made Us Immunex" book for a more complete history.

This collection documents the public face of Immunex from its founding to its merger with Amgen. Donations were restricted to items in the public domain; therefore it does not include correspondence, internal memos, and the like. The annual reports show not only the growth of the company throughout its existence but also the changing way it portrayed itself to investors and other interested parties. News clippings document the way in which the company, its finances, and its products were viewed. Materials such as marketing brochures and slide programs show the way in which the company sold its products and spread the word about its science. Finally, a stock prospectus and the merger prospectus shed light on the finances of the corporation.

Several items in the collection require explanation: These statements of values important to the culture of Immunex were created by a committee of employees. The original color documents were framed and hung in the company's offices.This book was created by two professional writers working with a committee of Immunex employees. These 30-second spots were shown on the scoreboard at Safeco Field during Mariners baseball games.These documents were framed and displayed at Immunex headquarters. They represent important moments in the company's history.

The collection is open to the public by appointment.

The Museum of History & Industry is the owner of the materials in the Sophie Frye Bass Library and makes available reproductions for research, publication, and other uses. Written permission must be obtained from MOHAI before any reproduction use. The museum does not necessarily hold copyright to all of the materials in the collections. In some cases, permission for use may require seeking additional authorization from the copyright owners.

Immunex Corporation Collection, Museum of History & Industry, Seattle

Amgen and former Immunex employees donated the records to the museum in 2003.

Processed by Julie Kerssen in 2003.

These materials are part of a donation that also included a number of artifacts. These artifacts are cataloged and stored separately by MOHAI's Collections Department.

 Biotechnology -- Washington (State) -- Seattle Medicine and Health Science Seattle 1 1 Annual reports 1983-1989 1 2 Annual reports 1990-1994 1 3 Annual reports 1995-1998 1 4 Annual reports 1999-2001 1 5 Annual reports, duplicates 1985-1998 1 6 Brochures, flyers, photos undated 1 7 Enbrel slide program and slide lecture notes 1999 1 8 Immunex/Amgen merger prospectus 2002 1 9 Immunex values undated 1 10 Immunex website CD 2002 1 11 Journal article title sheets 1986-1997 1 12 News clippings 1985 June-1991 May 1 13 News clippings 1991 June-July 1 14 News clippings 1991 August-2000 January 1 15 Stock prospectus 2000 1 16 "What's Made Us Immunex" (book) 2002 1 Enbrel Slide Resource Binder undated 1 Videos (see separate listing below) circa 1998-2000 2 Wall of Fame undated 3 Wall of Fame undated 4 Wall of Fame undated Series 2003.15.2 Videos All videos are located in Box 1.

Compilation Tape, Immunex Corporation 8/16/00 #2705. "First Therapy Approved for Secondary Progressive Multiple Sclerosis, NOVANTRONE, Offers New Hope for Patients Whose MS Continues To Worsen" FDA Approves First Treatment for Worsening Progressive Multiple Sclerosis, 3/8/2000 ENBREL Receives FDA Approval for Treatment of Rheumatoid Arthritis: A Breakthrough in RA Therapy New Treatment for Psoriatic Arthritis ENBREL (ETS NERC EPT [sic; actually etanercept]) Approved For First Line Treatment of Patients with Moderately to Severely Active Rheumatoid Arthritis Immunex All-Stars VNR [Video News Release] The History Channel -- "Lindbergh Flies Again" Study Results Positive for New Approach in Treating Juvenile Rheumatoid Arthritis, 11/9/1998 Corporate Identity Video Immunex Mariners Game 9/27/2000 -- Science Education at Immunex Orbis Broadcast Group Special Report: The New England Journal of Medicine Reports Enbrel Most Dramatic Advancement in Years in Treating Juvenile Rheumatoid Arthritis Immunex Biotech Brain Quiz Premera Blue Cross "Immunex" commercial